Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study

What Was Tested

The paper reports a study of Insulin Lispro, published as a randomized controlled trial.

The aim of the study was to compare lispro (LP) and Insuman(R) (I) insulin in continuous subcutaneous insulin infusion (CSII) therapy with respect to blood glucose control as expressed by the standard deviation of blood glucose (SD(BG) ) and HbA(1c) and to monitor the well-being (WBQ) and treatment satisfaction (DTSQ) parameters during such treatment.

Why It Was Studied

Forty-one IDDM patients who had used CSII for at least 6 months participated in an open-label, randomized, cross-over, multicenter study for 4 months (2 months LP and 2 months I or vice versa).

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, open-label, crossover and multicenter.

The participants were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

Everyone knew when Insulin Lispro was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.

Running at several centres spread the Insulin Lispro study over different clinics and patient groups.

Boluses with LP were given 5 min before each meal and with I 30 min before each meal.

What Was Measured

PubMed files the paper under topics including Affect, Blood Glucose, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Lispro.

The publication is from 2000 (Diabetes & metabolism), a journal based in France.

More context: the Insulin Lispro compound page, all human trials.